NCT02671383View on ClinicalTrials.gov

Evaluation of Low-dose Darunavir in a Switch Study

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 16, 2018

Study Completion Date

May 16, 2018

Conditions
HIV Infections
Interventions
DRUG

Darunavir

Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.

DRUG

Lopinavir

Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.

Trial Locations (1)

2196

Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg

All Listed Sponsors
collaborator

Medical Research Council, South Africa

OTHER

lead

Willem Daniel Francois Venter

OTHER

NCT02671383 - Evaluation of Low-dose Darunavir in a Switch Study | Biotech Hunter | Biotech Hunter